See more : Develia S.A. (DVL.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Incannex Healthcare Limited (IXHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incannex Healthcare Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Bigbloc Construction Limited (BIGBLOC.NS) Income Statement Analysis – Financial Results
- Sinoseal Holding Co., Ltd. (300470.SZ) Income Statement Analysis – Financial Results
- Contact Gold Corp. (C.V) Income Statement Analysis – Financial Results
- Glacier Media Inc. (GVC.TO) Income Statement Analysis – Financial Results
- BioInvent International AB (publ) (BOVNF) Income Statement Analysis – Financial Results
Incannex Healthcare Limited (IXHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.incannex.com.au
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00K | 0.00 | 540.17K | 1.42M | 417.45K | 1.09K | 749.19K | 216.77K | 68.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 4.38K | 683.84K | 310.80K | 0.00 | 387.89K | 396.97K | 48.92K | 13.76K | 430.76K | 757.99K | 1.22M | 41.75K | 391.02K | 0.00 | 0.00 | 0.00 | 15.29K |
| Gross Profit | 12.00K | 0.00 | 535.79K | 739.07K | 106.65K | 1.09K | 361.30K | -180.20K | 19.38K | -13.76K | -430.76K | -757.99K | -1.22M | -41.75K | -391.02K | 0.00 | 0.00 | 0.00 | -15.29K |
| Gross Profit Ratio | 100.00% | 0.00% | 99.19% | 51.94% | 25.55% | 100.00% | 48.23% | -83.13% | 28.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.88M | 41.66M | 3.71M | 3.54M | 1.46M | 516.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.83M | 7.93M | 193.99K | 74.31K | 315.85K | 231.80K | 573.43K | 612.04K | 268.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 348.00K | 84.00K | 1.90M | 3.26M | 280.35K | 66.56K | 901.40K | 423.04K | 53.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.17M | 8.01M | 4.66M | 4.84M | 1.35M | 375.15K | 2.58M | 1.85M | 509.60K | 486.81K | 397.05K | 1.37M | 1.15M | 2.73M | 361.62K | 513.85K | 826.11K | 839.29K | 107.68K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.49K | -93.16K | -202.43K | -152.02K | -180.81K | 0.00 | -131.67K | -27.52K | -24.19K |
| Operating Expenses | 30.05M | 49.67M | 8.37M | 8.40M | 2.81M | 891.96K | 2.58M | 1.85M | 509.60K | 486.81K | 390.56K | 1.46M | 1.35M | 2.88M | 180.81K | 513.85K | 957.78K | 866.81K | 131.87K |
| Cost & Expenses | 30.05M | 49.67M | 8.38M | 9.09M | 3.12M | 891.96K | 2.97M | 2.24M | 558.53K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Interest Income | 206.00K | 244.01K | 4.55K | 2.00K | 3.05K | 1.11K | 2.36K | 6.53K | 424.25 | 3.18K | 16.34K | 122.80K | 126.22K | 99.59K | 32.62K | 6.91K | 224.50K | 44.01K | 1.18K |
| Interest Expense | 0.00 | 3.01K | 218.07 | -10.46 | -89.80 | 60.83K | 9.98K | 37.56K | 89.76 | 99.84K | 160.04K | 195.54K | 194.91K | 93.67K | 107.56K | 35.09K | 10.92K | 5.05K | 15.59K |
| Depreciation & Amortization | 103.00K | 23.00K | 7.84M | 7.64M | 28.91K | 29.95K | 42.33K | 23.27K | 11.93K | 13.76K | 36.25K | 29.41K | 42.58K | 41.75K | 45.15K | 41.29K | 41.84K | 8.56K | 340.77 |
| EBITDA | -18.50M | -13.62M | 0.00 | 0.00 | -2.59M | -861.46K | -2.22M | -2.03M | -490.22K | -2.09M | -12.10M | -13.22M | -3.27M | -4.43M | 2.38M | -2.79M | -932.05K | -820.09K | -163.01K |
| EBITDA Ratio | -154,200.00% | 0.00% | 0.00% | 0.00% | -619.34% | -79,012.56% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.04M | -49.67M | -7.84M | -7.66M | -2.70M | -890.87K | -2.22M | -2.03M | -490.22K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Operating Income Ratio | -250,341.67% | 0.00% | -1,450.78% | -538.64% | -646.62% | -81,709.63% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.61M | 857.00K | -2.45M | -863.45K | -12.42K | -110.40K | -160.17K | -14.11M | -59.59K | -1.70M | -11.48M | -11.23M | -936.03K | -1.64M | 2.80M | -2.23M | 14.81K | 41.67K | -31.78K |
| Income Before Tax | -18.43M | -48.81M | -10.29M | -8.53M | -2.71M | -1.00M | -2.38M | -16.14M | -549.82K | -2.20M | -12.30M | -13.45M | -3.51M | -4.56M | 2.23M | -2.87M | -984.81K | -833.71K | -178.94K |
| Income Before Tax Ratio | -153,575.00% | 0.00% | -1,904.94% | -599.33% | -649.59% | -91,835.01% | -317.25% | -7,444.24% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -204.00K | -229.80K | 0.00 | -88.06K | -1.32M | -1.09M | -278.89K | 0.00 | 0.00 | -18.10K | 0.00 | 0.00 | 0.00 |
| Net Income | -18.46M | -48.81M | -10.29M | -8.53M | -3.24M | -1.91M | -2.18M | -15.90M | -549.82K | -2.11M | -10.98M | -12.36M | -3.23M | -4.56M | 2.23M | -2.85M | -984.81K | -833.71K | -178.94K |
| Net Income Ratio | -153,825.00% | 0.00% | -1,904.94% | -599.33% | -776.62% | -175,041.70% | -291.24% | -7,336.20% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -1.07 | 0.90 | -1.72 | -0.73 | -1.18 | -0.37 |
| EPS Diluted | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -0.73 | 0.51 | -1.72 | -0.73 | -1.13 | -0.37 |
| Weighted Avg Shares Out | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 4.05M | 2.47M | 1.65M | 1.35M | 706.01K | 481.06K |
| Weighted Avg Shares Out (Dil) | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 5.88M | 4.37M | 1.65M | 1.35M | 738.99K | 481.06K |
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of...
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial...
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou...
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways:...
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year...
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed...
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
NEW YORK and MELBOURNE, Australia, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies is pleased to announce that it has received...
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant...
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced...
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the...
Source: https://incomestatements.info
Category: Stock Reports